# MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma

> **NCT00853307** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 31 (actual)

## Conditions studied

- Ovarian Carcinoma

## Interventions

- **DRUG:** Alisertib

## Key facts

- **NCT ID:** NCT00853307
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-03-23
- **Primary completion:** 2009-11-23
- **Final completion:** 2011-01-27
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2022-04-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00853307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00853307, "MLN8237 for Treatment of Participants With Ovarian, Fallopian Tube, or Peritoneal Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00853307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*